Skip to Main Content
Diseases of the Endocrine System | Genetics - Adult, Phase I-II

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)

What is the purpose of this trial?

The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.

  • Trial with
    Vivet Therapeutics, SAS
  • Ages
    18 years - 60 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Daksshi Hettiarachchi

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    07/19/2024
  • Study HIC
    #2000028887